Codice QR

Analysis of Baseline Molecular Factors Associated With the Risk of Central Nervous System Progression Among Alectinib-Treated Patients With ALK–Positive NSCLC

Introduction: Despite receiving alectinib therapy, patients with ALK-positive NSCLC remain at risk of central nervous system (CNS) progression. Our retrospective study aimed to identify baseline clinical and molecular factors associated with the risk of CNS progression in this patient subset. Method...

Descrizione completa

Salvato in:
Autori principali: Lianxi Song, MD, Huan Yan, MD, Qinqin Xu, MD, Chunhua Zhou, MD, Juan Liang, MD, Shaoding Lin, MD, Ruiguang Zhang, MD, Juan Yu, MD, Yang Xia, MD, Nong Yang, MD, Liang Zeng, MD, Yongchang Zhang, MD
Natura: Artigo
Lingua:Inglês
Pubblicazione: Elsevier 2024-12-01
Serie:JTO Clinical and Research Reports
Soggetti:
Alectinib
CNS progression
Biomarker
ALK
Non–small cell lung cancer
Accesso online:http://www.sciencedirect.com/science/article/pii/S2666364324000997
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi